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Introduction
First, although I don't want to be definitive to  the point of
excluding important  issues,  some definition of the  term
"biotechnology"  as applied to agriculture  is probably in order.  One
such definition is  "the use of living organisms  in agriculturally
related processes on farms and in industry."  but, by that
definition, we have had biotechnology applications  in agriculture  for
a long time.  And, it  is  some of the more recent applications which
are  of particular interest to  the topic at hand.  The Division of
Agriculture's  Committee on Biotechnology of the National Association
of State Universities and Land Grant Colleges,  "NASULGC,"  (Progress
Report III,  November, 1984) identifies these new techniques  in
biotechnology to include  "...plant and protoplast culture, plant
regeneration, somatic hybridization,  embryo transfer and recombinant
DNA approaches including gene  identification, characterization,
splicing, replication, regulation and transfer."  And, although this
list is  not exhaustive, these are probably the major techniques  that
should be  on the  agenda for any current discussion of policy
implications  for agriculture of biotechnology research and
application.  Lest we be unduly constrained in perspective, however,
we might keep  in mind the contention of Rifkin  (1983)  and others  that
"Biologists now view living organisms as  information systems"  and
that  "DNA is  the depository and distributor of information."
*This  manuscript represents a revised version of a discussion
prepared for  the Agricultural  Research Policy Seminar, North Star
Inn, Minneapolis, MN, April 18,  1986.This perspective opens up a dramatically large field of biotechnology
with a host of future policy issues waiting in the wings.
Importance of Biotechnology to Production Agriculture
Several years ago,  I was involved in a technology assessment  for
commercial corn production in the U.S.  (Sundquist, Menz  and Neumeyer,
1982).  As we tried to project the  importance of various  technologies
into  the future,  the emerging biotechnologies took on an increasing
but highly uncertain future role.  And, existing technologies,  except
for technology  trend associated with conventional plant breeding,
took on a declining future role (Figure 1).  My current perspective
is  to push back several years  the time line  (from that shown in
Figure 1) for major impacts of biotechnology  in corn production and
other major field crops but to recognize the possibility of some
major near term impacts  in the livestock production sector,
particularly in milk and red meat production.
Although it appears that biotechnology may play a proportionally
smaller  role in the  developing world than  in the U.S.  over the next
10-15 years,  it could be a major source of potential total
productivity gain there as well toward the end of this period.
Research Resources
From the standpoint of research resources,  in 1982  an estimated
283  faculty FTE from the State Agricultural Experiment Stations  (SAES)
in the U.S. were reported committed to biotechnology research, and a
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input  and production area.l  This number increased by  90 in  1984 and
was projected to  increase another 151 by 1986.  If  this projection
was  realized,  the number of SAES  scientists working on biotechnology
will have  almost doubled over only 4 years  (NASULGC, 1985).  State
Agricultural Experiment Station expenditures  for sponsored
biotechnology research  in 1984 approached $50 million and there has
been a corresponding rapid increase  in biotechnology research  in ARS.
Moreover, the private  sector is  funding biotechnology R & D like  it
has never funded research in any other technology area.  Thus  there
is  little  question that the  topic  "the  policy implications  for
agriculture  of biotechnology research"  is  already a relevant one.
And policy issues will almost certainly increase  rapidly in number in
the near future.
Policy Perspectives
It  is  already clear that  the  identification of major policy
issues surrounding biotechnology research  and its agricultural
applications varies greatly depending on the personal interests and
value perspectives of the  individuals,  organizations and institutions
involved.  For example, most agricultural scientists  (and many
general biological  scientists) see  the application of new
biotechnology techniques  to agriculture as  a potential  "bonanza of
opportunity."  On the other hand, Jeremy Rifkin  (1983)  and others,
1 A small percentage of faculty FTEs,  no more than an estimated 10-15 percent  of the total,  were  involved in biotechnology
applications  for food processing and manufacturing.
3particularly many individuals and groups with selected environmental
and genetic manipulation concerns,  see  it in a very negative context.
And, as  is  the case  for most issues which become major items  for
policy deliberation, there are substantive areas  for disagreement.  I
turn first to  a look at some topics  affecting future biotechnology
policies from a commercialization perspective.
The Office of Technology Assessment (1984) identified 10 factors
important  in determining the future position of the U.S.  and other
countries  in the  commercialization of biotechnology:
1)  Financing and tax incentives for firms.
2)  Government funding of basic and applied research.
3)  Personnel availability and training.
4)  Health, safety and environmental  regulation.
5)  Intellectual property law.
6)  University/Industry Relations.
7)  Antitrust law.
8)  International technology transfer,  investment and trade.
9)  Government targeting policies  in biotechnology.
10)  Public perception.
All 10  of these  factors have policy implications although OTA
considers  the  first 3 to  be most important, the next  3 of moderate
importance,  and the last 4 of least importance.  It is  probably  the
case  that this  list includes most of the major factors which will be
involved in policy deliberations vis-a-vis  the rate and extent of
commercialization of biotechnology processes  and products.
4There  is  also a very different perspective from the
"commercialization goal" of OTA and others  in both the public and
private sectors.  This  is  the perspective of those who see
biotechnology as  "An Age of Intervention."  This  "intervention"
refers to  the expanded use and modification of life forms for human
ends.  Among the basic value questions raised is  the  one of modifying
the human life  form itself for other than the correction of health
impairing genetic defects.  Another concern is  for the release  of new
life forms into the  environment and the potential  adverse effects of
such release.
Regal  (1985a) provides the well reasoned perspective  (and
probably one with rather widespread acceptance) that,  "the  challenge
with biotechnology will be to maximize its benefits to  society and to
minimize health and environmental hazards and other costs."  Regal
goes on to  say that "a most critical need is  for better  information-
flow between those seeking profits and those seeking to understand
the  implications of  the new creations,  as well as  those seeking to
ensure the  effectiveness and safety of the new power."  The latter
statement would appear to  give considerable prominence to policy
issues related to  trade secrets, intellectual property law, health
and safety considerations,  antitrust law, University/Industry/
Government relations,  etc.,  which were given somewhat lower priority
than commercialization in the OTA perspective.
An additional perspective provided by Kalter  (1985) and by a
recent OTA study  (1986)  is  that the  emerging biotechnologies  will
5probably speed up the  structural change in U.S. agriculture  to  fewer
and larger  farms.
One could go on to  other references and to other general
perspectives, but perhaps  it  is more useful at  this juncture  to  focus
some on the several major policy issue areas stemming from agricul-
turally related biotechnology.
Policy Issues
One approach to discussion of the policy issues  topic, and the
one used here,  is  to  try to categorize major policy concerns  into
several groups while recognizing that many of these categories  are
highly interdependent and overlapping.
Genetic Modification and Diversity
Embodied in the notion of the  "age of intervention"  is  the
implication of a major shift to genetic engineering rather  than
"mutation and natural selection" as the mechanism by which the
evolutionary process  is  guided.  A quote attributed to Robert
Sinsheimer is  the following:  "In  the hands  of the genetic  engineer,
life forms could become extraordinary tinkertoys and life  itself just
another design problem."  It would appear that such a process, if  it
develops, could result  in a major change in the incentives  for
maintaining natural genetic diversity unless public policies are
developed to maintain the preservation of existing germplasm.  And,
major varietal performance gains via genetic  engineering could result
in excessively heavy dependence on (vulnerability for)  these new
"genetically engineered"  lines  should major pest or  environmental
6problems  emerge.2 Moreover, such new superior genetically
engineered lines  could exert very heavy pressure on existing
"natural" lines.  In any event,  there does  seem to be  an inherent
potential  for downgrading the  importance of natural genetic
diversity.3 Thus,  there  arises a new imperative  for policies which
encourage  the preservation of such diversity.  Also important  is  the
continuation of conventional plant and animal breeding programs which
draw on the  naturally existing gene pool as well as  incorporating  the
genetic  inputs  from biotechnology.  In short, biotechnology  is not a
substitute  for conventional breeding and selection work.  Our
research funding policies need to recognize  this  latter fact.
Health and Safety Implications
According to  Regal  (1985b),  "It  is  safe  to  say that contrary to
other implications,  no scientist  ...  will now claim that all  or even
most recombinant DNA organisms will be categorically dangerous.  This
is  a dead scientific  issue in  1985."  But,  in another context,  "there
is  an oversimplification of ecological  issues  in the  claims that  it
will be quite safe  to  release essentially any genetically  engineered
form into  the environment."
2 In addition to major disease and insect problems,  are  the
potential hazards of acid rain, the greenhouse effect of increased
atmospheric CO2, increased salinity and toxic  salts on  irrigated
lands,  etc.
3There is,  on the  other hand, a potential for protecting
naturally occurring genetic diversity in anticipation of the
capability to utilize  this diversity via gene transfer.  Both
viewpoints, however, would appear to support  the argument for
protecting naturally existing diversity.
7Thus,  the environmental  safety debate appears  to have shifted
generally from one of concern about genetically engineered forms
developing  into  "rogue" organisms  that can become  "dangerous
cannons  loose on the deck"  to  one of concern for responsible  testing
and safety  regulations.  The recent controversies regarding the  field
testing of  "ice minus" bacteria and a genetically engineered vaccine
for pseudorabies  suggest that agriculturally related biotechnologies
will be  in the  forefront of safety issues.  In March, 1986,  EPA
suspended the permit for field testing of the  ice minus bacteria
signaling that this agency will enforce its  regulatory policy
regarding biotechnology experiments.  This permit was  only recently
reinstated.
Human health issues will almost certainly be of crucial
importance  for biotechnology applications  in animal agriculture and
in the  food processing industry.  Although the  Federal Food and Drug
Administration has rather clear cut responsibilities  in the  food
health and safety area,  the line of responsibility in ensuring safety
in crop and livestock related applications  is  still being sorted out.
As of this date,  industry leaders  are  stepping up pressures  for
federal and state governments  to  forge  a regulatory apparatus  to
ensure  that  agricultural biotechnology experiments  can go  forward
without excessive delays and clearance costs.  In response, EPA and
USDA in mid-1986 unveiled their proposed regulatory matrix.  There
appears good reason to believe that key regulatory issues relating to
product field testing and release will eventually be worked out.  But
these  regulatory issues will be a major policy arena over  the next
8decade or more.  And the current status of regulation is  not an
encouraging one  (Science, 1986).  Thus,  it is  already clear  that
agricultural applications  of biotechnology will not be given the  open
ended license of their predecessor agricultural  technologies.
Neither, however, should they be subjected to  such excessive
regulatory delay as  to virtually ensure their economic  failure.
Dividing the Research Agenda and Responsibilities
Much biotechnology development requires research inputs  from
both the basic and the  applied sciences.  And the public research
institutions and the private industrial laboratories can both
contribute to  the process.  But how should the R & D investments be
financed?  Who should pay the bill?  What economic incentives  for
generating additional private sector R & D will be appropriate?
. X
How will public (and private)  interests be protected in the  granting
of such incentives?  What kind of public sector-private  sector
institutional arrangements  (such as joint ventures) should be
supported for the  development of new biotechnology?4 How does  one
ensure, for example, that the basic scientific work which permits the
development of new biotechnologies gets done?  These  several latter
questions  imply an even broader policy question.  How do we
effectively draw together the resources and capabilities of the
4Discussion of this  topic and a comprehensive prototype legal
arrangement  for University-Private Sector collaborative  arrangements
for biotechnology research is  contained in  Progress Report  III  of  the
Division of Agriculture Committee  on Biotechnology, NASULGC,
"Emerging Biotechnologies  in Agriculture:  Issues and Policies,"
November, 1984.
9private sector, the  research universities, and the  government to
deliver the biotechnologies which can provide crucial future
productivity growth?5
The private sector generally welcomes  the contribution of public
research to basic or  theoretical science.  And, although a number of
large private sector  firms can undertake  to do basic and theoretical
science,  the preponderance of private sector firms cannot afford to
do so.  Thus, a strong case can be made for publicly supported basic
research.  Private sector reaction to public research on applied
technologies  is, however, sometimes a different story.  This should
not be  surprising since it  is mainly  through the development and
marketing of applied technologies  that the private sector enters  the
market economy.  Their capacity to do  this profitably relates to
their ability to develop and protect a market  for their product(s).
As  a result, many private sector firms will oppose  any widespread
funding of applied research by the public sector.  But,  they would,
if possible, be willing to enlist the  services of public sector
researchers  to assist them in their product and process related R & D.
The question of public versus private research did not have its
origin with the emerging biotechnologies.  Rather  it has been around
in one form or  another for  a long time.  In recent years,  for
example,  the question of whether or not the public sector (USDA and
the SAES)  should be involved in developing crop varieties for  farmer
5 There is  a widespread belief that the  current prominence of
Japan, West Germany and some other countries  in world technology and
trade  is  due  in part to more effective working alliances between
government and the private  sector than now exists  in the U.S.
10use or  should leave this  to  the private sector has been a continuing
issue.  This policy issue will become even more  intense when genetic
engineering begins  to  play an important role in applied plant
breeding (varietal development).  Yet  it seems  somewhat of a policy
imbalance  to ask the  tax paying public to  support only basic research
in the public sector and to turn their results over to  the private
sector firms to  exploit the potential  for economic gain via the
application of biotechnology techniques.
The several  issues  of the  division of public-private research
identified in the preceding paragraphs probably focus mainly on three
key mechanisms of public policy (Sundquist, 1983):
1.  establishing constructive mechanisms  for
joint public-private  sector planning  for
research priorities and for  the conduct
of R & D work,
2.  providing funding and other support
services for public  sector research, and,
3.  granting proprietary rights and tax
benefits to private sector  firms.
Appropriate developmental strategy should strive  to  capitalize
on the  interests, capabilities,  and comparative advantages  of both
private  sector firms  and public  sector institutions.  For example,
the  comparative advantage of the USDA/SAES System lies  in its
extensive and widely dispersed research base  (both professional staff
and  facilities),  its  extensive feedback system (particularly with
producers),  and its  training capabilities  (particularly at  the
11graduate  level).  The comparative advantage of the private sector
centers on its unique profit incentives and its vast capabilities  to
develop biotechnology processes and products  and to  market the
resulting output.
One of the critical  issues relating to  the balance  of public and
private research is  the  stagnation of public funding of agricultural
research  (actually declining real public research budgets  since the
late  1970s)  and the  large  infusion of new R & D funding in the
private sector.  This has resulted in the private sector R & D budget
dominating the public research budget by a substantial margin (Ruttan
1982).  Thus  if public research is  to  play a continuing important
role in biotechnology, it will either have  to  improve its  access  to
funding for that purpose or leave other  important research areas  with
diminished financial support.
Both new and tested mechanisms  can be used for  the funding of
public sector research for biotechnology.  Both the traditional  (or
an improved) federal formula funding for the Agricultural Experiment
Stations  and a strong competitive  grants program can aid the research
process.  So  can a well financed research program in ARS.  In
addition, key regulatory agencies need funding support  for evaluative
(technology testing) research.
The process  of granting proprietary and quasi-monopoly rights  to
businesses for biotechnology by patents, copyrights, and other
licensing mechanisms will undoubtedly be an area of active  future
public policy.  So will  issues relative  to  investment  tax credits and
other  tax exemptions  or write-offs.  In both areas, public policy
12will have to be based on an evaluation of trade-offs.  But two
principles  should probably be  of overriding public concern.  First,
the granting of proprietary rights should not be permitted to
excessively slow the broad availability of productive new technology
or  to allow franchise holders to excessively exploit new income
streams.  In short, excessive monopoly powers should not be granted
to technology developers.  Second, tax benefits for  technology
producers and/or users are appropriate only for those biotechnologies
which have been determined not be have broad based adverse effects.
In summary, it  is not difficult to  identify a more optimal mix
than currently exists of mechanisms for joint public-private sector
planning of research priorities and conduct of R & D work.  In the
process  the benefits  of biotechnology would be more broadly dispersed
within the agricultural  industry and to  other interest groups
(environmentalists, consumers, and to  the R & D community generally).
Moreover, a joint public-private research effort could help
accomplish the  critical information flow identified by Regal in an
earlier section of this  discussion.
Intellectual Property Rights.  Information Dissemination and Industry
Structure
Policy implications of intellectual property rights  are already
embodied in the previous topic of patents and licenses.  The U.S.
Board of Patent Appeals,  in a reversal of policy,  in 1985  ruled that
Section 101 of the U.S. Patent Act does  indeed apply to  seeds,
plants,  plant parts, tissue cultures,  etc.  This  case, brought by a
local firm, Molecular Genetics,  Inc.,  involved a claim made  for new
13corn plants and seeds that contain high levels  of the amino acid
tryptophan.  This decision did for plants what the Supreme Court  did
for  living microorganisms  in 1980 by ruling that  the  latter were
patentable products.  The  full  interpretation and impact of these
patent rights will undoubtedly be determined still further by future
actions  in the courts.
While these patentability rulings provide much desired
protection for private sector R & D and thus provide  incentive for
biotechnology development,  they raise the  specter of adverse
consequences as well.  The needed improvement  in information flow
called for earlier by Regal will not be encouraged by extensive
protection of proprietary products.  Also,  there is  increasing
evidence that extensive protection of biotechnology through patenting
and licensing rights will result  in increased concentration among
those agribusiness  sectors producing new biotechnology products.
Since information on most prior agricultural technologies has been
available through the public sector, industrial  firms have been able
to concentrate  the market only if  there were major scale economies in
product manufacturing and/or marketing as  in  the case, for example,
of major equipment items  such as  tractors and harvesters.  It  seems
clear that some of the major chemical companies now believe  that  they
will be able to capture substantial economic  rents in  the future
through development and control of agricultural applications  of  the
emerging biotechnologies.  There can be no other explanation of their
widespread activities  to acquire  farm input firms  (such as  seed
companies)  and firms  specializing in biotechnology R & D.
14Structure of the  Farming Sector
Recent analyses  (OTA, 1986;  Kalter, 1985;  Buttel,  1986) suggest
that biotechnology applications  in the  farming sector will  result in
a continuation of the structural adjustment to  fewer and larger farms
but will not result  in a take over of farming by corporations.  These
results are exemplified from the OTA report in Table  1.  Although
most biotechnology applications in farming may be  rather scale
neutral, they will probably be adopted as part of more technically
complex farming systems which will be more easily adopted by
commercial farmers than by small or part-time farmers.  The number-
size  adjustment projected to the year  2000  shown in Table 1 would
probably result  in significant increases  in agricultural
productivity.  It will, however, undoubtedly be opposed on several
policy fronts.  The following quote  from the March 23,  1986  issue of
the New York Times  illustrates the nature of at least  some of the
expected resistance to  commercial release of the Bovine Growth Hormone.




of farms  Percent of  of farms  Percent of
Sales  class  (thousands)  all  farms  (thousands)  all  farms
Small  and part-time  .....  1,936.9  86.0  1,000.2  80.0
Moderate  ................  180.7  10.0  75.0  6.0
Large and very large  ....  121.7  4.0  175.0  14.0
Total  ...............  2,239.3  100.0  1,250.2  100.0
SOURCE:  Office of Technology Assessment (1986).
15Dairy  farmers in Wisconsin, for instance, are
organizing to prevent the marketing of a
genetically engineered hormone that will  raise
daily milk production by 30 percent in
the  average cow.  A Cornell University study
predicted that the use of this hormone would reduce
by half the number  of dairy farms  and shift the
center of production from the Upper Middle West to
the Southwest, where farms are
much larger and presumably better able to
afford new technology.  "There is  going  to be
a big fight in farm country over this
technology,"  said Jeremy Rifkin,  president of
the Foundation of Economic Trends,  a
Washington-based group.  "Farmers are not
going to  roll over.  If they do,  they're
dead."
Although it  seems unlikely that  the release of the bovine
growth hormone will be prevented by regulatory constraints,  there
might well be efforts  (of as yet undetermined success) to protect
dairy producers via milk quotas or other policy devices.6 And,
although concern needs  to be realized for impacted dairy farmers
6 The  only currently identified valid opposition to  the bovine
growth hormone appears  to  be in terms  of the potential adverse economic impact on some producers.  If constraints are  imposed on implementation of the  technology for economic reasons,  it will be the  first incidence of technology constraints imposed for that reason alone.
16and regional economies, poorly conceived policies could offset a
major part of the potential productivity gains  from the emerging
technologies while providing little or no long term assistance to
targeted beneficiaries.
Technology Transfer
A number of important policy issues could be discussed under
the heading of technology transfer, but I will mention only  three
which have been indirectly implied earlier  in this  discussion.
First, the public agricultural research system in the U.S.  stands
to  lose much of its broad based farmer support system  if its
researchers choose to communicate mainly with private sector  firms
in the  development of new biotechnologies.  If this were to happen,
the farm and rural business clientele could withdraw much of its
support for publicly funded research.  The policy issues here
relate to retaining or redeveloping an effective technology
transfer linkage with this  important (mainly rural) clientele
group.  ARS has instituted a mechanism for  routinely reporting
their research (technology) achievements  through the Agricultural
Extension Information System.  But this system needs strengthening.
I believe  also that  the Land Grant Universities need to  seriously
undertake the upgrading of the biotechnology  transfer process  for
their key farm and agribusiness clientele.
A second major issue  regarding technology transfer relates  to
the potential for private firms  to excessively capture exclusive
property rights to biotechnologies via patents  and licenses.  If
17accomplished excessively, this capture could result not only  in the
economic exploitation of farmers by agribusiness  firms but  it  could
also result in the public sector losing  its access to  information
about the relevant new technology which should be  transferred to
farmers.  Here the major policy issue relates back to  the need to
avoid the granting to private sector firms  of excessive monopoly
rights.
A third issue pertains to  technology transfer between
countries.  I have neither the space or  the expertise  to develop
this  issue here.  But, clearly the  issue  takes on different
dimensions when we are considering transfer between developed
countries and between developed and developing countries.  There  is
an extensive evolving literature on this  issue and  its importance
well justifies  its attention in a separate discussion.
In Conclusion
The above discussion treats  only some of the policy
implications of biotechnology research and it  treats them very
lightly.  But, even this brief sampling of policy issues  suggests
that  some are very important and extend well beyond agriculture  to
basic ethical and human safety concerns.  Other  issues  are simpler
but  still involve important economic-environmental-structural trade
offs.  Our understanding of both can profit  from good
interdisciplinary research.
Although there  is a potential  for major productivity gains  for
production agriculture via the emerging biotechnologies, they will
18be subjected to much more  intensive policy debate and action than
has been the case for their predecessor agricultural  technologies.
And this  is probably as  it should be if done constructively.  The
latter requires a good informational base on which to draw.
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